The common adverse reactions (? 2%) reported in clinical trials were headache, nausea, and diarrhea.
Serious arterial and venous thromboembolic (TE) events have been reported at the recommended dose of plasma derived C1 esterase inhibitor products in patients with risk factors. Risk factors may include the presence of an indwelling venous catheter/access device, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptives or certain androgens, morbid obesity, and immobility. Monitor patients with known risk factors for TE events during and after administration.
C1 Esterase Inhibitor (Recombinant) is a recombinant analogue of endogenous complement component-1 esterase inhibitor (rhC1INH), purified from the milk of transgenic rabbits. The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways. It does this through inhibition of several target proteases within these pathways including activated C1s, kallikrein, factor XIIa and factor XIa. C1 esterase inhibitor has also been shown to inhibit the action of thrombin within the coagulation pathway, and tPA and plasmin within the fibrinolytic pathway. Deficiency of C1-inhibitor allows for increased plasma kallikrein activation and subsequent production of bradykinin. Additionally, C4 and C2 cleavage occurs resulting in auto-activation of the complement system. Down-stream effects of the lack of enzyme inhibition by C1 esterase inhibitor results in swelling due to leakage of fluid from blood vessels into connective tissue and consequently the presentation of hereditary angioedema (HAE).
Marketed as the product Ruconest (FDA), this drug is indicated for the treatment of acute attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency in adults. Intravenous replacement of C1 esterase inhibitor results in reversal of acute symptoms of HAE.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Etonogestrel | The risk or severity of thromboembolism can be increased when Etonogestrel is combined with Conestat alfa. |
| Desogestrel | The risk or severity of thromboembolism can be increased when Desogestrel is combined with Conestat alfa. |
| Megestrol acetate | The risk or severity of thromboembolism can be increased when Megestrol acetate is combined with Conestat alfa. |
| Levonorgestrel | The risk or severity of thromboembolism can be increased when Levonorgestrel is combined with Conestat alfa. |
| Dydrogesterone | The risk or severity of thromboembolism can be increased when Dydrogesterone is combined with Conestat alfa. |
| Progesterone | The risk or severity of thromboembolism can be increased when Progesterone is combined with Conestat alfa. |
| Medroxyprogesterone acetate | The risk or severity of thromboembolism can be increased when Medroxyprogesterone acetate is combined with Conestat alfa. |
| Norethisterone | The risk or severity of thromboembolism can be increased when Norethisterone is combined with Conestat alfa. |
| Ethynodiol diacetate | The risk or severity of thromboembolism can be increased when Ethynodiol diacetate is combined with Conestat alfa. |
| Norgestimate | The risk or severity of thromboembolism can be increased when Norgestimate is combined with Conestat alfa. |
| Drospirenone | The risk or severity of thromboembolism can be increased when Drospirenone is combined with Conestat alfa. |
| Allylestrenol | The risk or severity of thromboembolism can be increased when Allylestrenol is combined with Conestat alfa. |
| Cyproterone acetate | The risk or severity of thromboembolism can be increased when Cyproterone acetate is combined with Conestat alfa. |
| Norelgestromin | The risk or severity of thromboembolism can be increased when Norelgestromin is combined with Conestat alfa. |
| Gestodene | The risk or severity of thromboembolism can be increased when Gestodene is combined with Conestat alfa. |
| Hydroxyprogesterone caproate | The risk or severity of thromboembolism can be increased when Hydroxyprogesterone caproate is combined with Conestat alfa. |
| Dienogest | The risk or severity of thromboembolism can be increased when Dienogest is combined with Conestat alfa. |
| Medrogestone | The risk or severity of thromboembolism can be increased when Medrogestone is combined with Conestat alfa. |
| Norethynodrel | The risk or severity of thromboembolism can be increased when Norethynodrel is combined with Conestat alfa. |
| Norgestrel | The risk or severity of thromboembolism can be increased when Norgestrel is combined with Conestat alfa. |
| Altrenogest | The risk or severity of thromboembolism can be increased when Altrenogest is combined with Conestat alfa. |
| Gestrinone | The risk or severity of thromboembolism can be increased when Gestrinone is combined with Conestat alfa. |
| Nomegestrol | The risk or severity of thromboembolism can be increased when Nomegestrol is combined with Conestat alfa. |
| Lynestrenol | The risk or severity of thromboembolism can be increased when Lynestrenol is combined with Conestat alfa. |
| Gestonorone | The risk or severity of thromboembolism can be increased when Gestonorone is combined with Conestat alfa. |
| Chlormadinone | The risk or severity of thromboembolism can be increased when Chlormadinone is combined with Conestat alfa. |
| Methylestrenolone | The risk or severity of thromboembolism can be increased when Methylestrenolone is combined with Conestat alfa. |
| Norgestrienone | The risk or severity of thromboembolism can be increased when Norgestrienone is combined with Conestat alfa. |
| Promegestone | The risk or severity of thromboembolism can be increased when Promegestone is combined with Conestat alfa. |
| Quingestanol | The risk or severity of thromboembolism can be increased when Quingestanol is combined with Conestat alfa. |
| Demegestone | The risk or severity of thromboembolism can be increased when Demegestone is combined with Conestat alfa. |
| Etynodiol | The risk or severity of thromboembolism can be increased when Etynodiol is combined with Conestat alfa. |
| Nomegestrol acetate | The risk or severity of thromboembolism can be increased when Nomegestrol acetate is combined with Conestat alfa. |
| Hydroxyprogesterone | The risk or severity of thromboembolism can be increased when Hydroxyprogesterone is combined with Conestat alfa. |
| Norethindrone enanthate | The risk or severity of thromboembolism can be increased when Norethindrone enanthate is combined with Conestat alfa. |
| Quingestanol acetate | The risk or severity of thromboembolism can be increased when Quingestanol acetate is combined with Conestat alfa. |
| Algestone acetophenide | The risk or severity of thromboembolism can be increased when Algestone acetophenide is combined with Conestat alfa. |